Research Advances on Probiotics-assisted Therapy for Metabolic Dysfunction-Associated Fatty Liver Disease
10.12259/j.issn.2095-610X.S20250720
- VernacularTitle:益生菌辅助治疗代谢功能障碍相关脂肪性肝病的研究进展
- Author:
Jia XIONG
1
;
Jia ZENG
;
Xiaoxian ZHOU
;
Xin XU
;
Yanjiao WANG
;
Zhishuang WU
;
Jianzhong YIN
;
Fei MI
Author Information
1. 云南省公共卫生与生物安全重点实验室,云南 昆明 650500;昆明医科大学公共卫生学院,云南 昆明 650500
- Keywords:
MASLD;
Pathogenic mechanism;
Probiotics;
Adjunctive therapy
- From:
Journal of Kunming Medical University
2025;46(7):163-174
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic dysfunction-associated steatotic liver disease(MASLD)is a chronic liver condition intricately linked to metabolic abnormalities such as obesity,type 2 diabetes,dyslipidemia,and hypertension.The global prevalence of MASLD continues to rise,posing a significant public health challenge.The pathogenesis of MASLD is multifactorial,with the"multiple-hit"hypothesis suggesting that hepatic lipid accumulation,insulin resistance,oxidative stress,gut microbiota dysbiosis,and genetic factors collectively drive disease progression.Currently,clinical management primarily relies on lifestyle interventions;however,there is a lack of targeted pharmacological interventions,and there is an urgent need to investigate novel adjunctive therapeutic strategies.In recent years,probiotics have demonstrated potential value in MASLD treatment due to their capacity to modulate gut microbiota,enhance insulin sensitivity,and reduce liver inflammation.This review systematically examines the pathogenesis of MASLD and the limitations of existing therapeutic approaches,synthesizing the latest evidence of probiotics-assisted therapy for MASLD from the perspectives of animal studies and clinical trials.By analyzing the target mechanisms and molecular pathways of different strains(e.g.,Bifidobacterium,Lactobacillus),this review explores the translational potential of probiotics in MASLD treatment,aiming to provide a theoretical foundation and future research directions.
